Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM NASDAQ:GNFT NASDAQ:MOR NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.37-11.6%$1.18$0.46▼$7.49$8.29M-0.1110.24 million shs127,954 shsGNFTGENFIT$3.82-2.9%$3.98$2.55▼$6.42$196.76M1.142,827 shs2,836 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AMRKMerck & Co., Inc.$79.27+1.5%$80.41$73.31▼$120.30$196.16B0.3812.51 million shs11.90 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group-11.61%-24.31%+48.27%+47.31%-58.48%GNFTGENFIT-0.52%-1.55%+0.26%-10.86%-9.38%MORMorphoSys0.00%0.00%0.00%0.00%+1.94%MRKMerck & Co., Inc.+1.41%-6.54%-3.75%-4.65%-29.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.0079 of 5 stars0.05.00.00.00.61.70.6GNFTGENFIT1.6953 of 5 stars3.53.00.00.01.90.00.0MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/AMRKMerck & Co., Inc.4.997 of 5 stars3.25.05.04.24.01.73.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/AGNFTGENFIT 3.00Buy$13.00240.76% UpsideMORMorphoSys 0.00N/AN/AN/AMRKMerck & Co., Inc. 2.35Hold$107.4435.53% UpsideCurrent Analyst Ratings BreakdownLatest MRK, MOR, APM, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025MRKMerck & Co., Inc.Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$97.00 ➝ $90.007/10/2025MRKMerck & Co., Inc.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $98.005/20/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Cautious5/14/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$115.00 ➝ $84.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K17.05N/AN/A$2.20 per share0.62GNFTGENFIT$76.77M2.48$0.07 per share56.26$1.50 per share2.54MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17MRKMerck & Co., Inc.$64.17B3.10$9.61 per share8.25$18.33 per share4.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/AN/AGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AMRKMerck & Co., Inc.$17.12B$6.4912.218.010.7925.79%41.63%16.58%N/ALatest MRK, MOR, APM, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.244.09%N/A49.92%14 YearsLatest MRK, MOR, APM, and GNFT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/22/2025MRKMerck & Co., Inc.quarterly$0.813.97%9/15/20259/15/202510/7/20255/27/2025MRKMerck & Co., Inc.quarterly$0.814.18%6/16/20256/16/20257/8/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22GNFTGENFIT0.081.231.23MORMorphoSys4.981.381.38MRKMerck & Co., Inc.0.691.411.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%GNFTGENFIT2.24%MORMorphoSys18.38%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%GNFTGENFIT4.20%MORMorphoSys0.05%MRKMerck & Co., Inc.0.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableMRKMerck & Co., Inc.75,0002.51 billion2.51 billionOptionableMRK, MOR, APM, and GNFT HeadlinesRecent News About These CompaniesLeerink Partnrs Issues Negative Forecast for MRK Earnings1 hour ago | americanbankingnews.comMerck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim CramerAugust 1 at 4:58 PM | insidermonkey.comMerck & Co., Inc. (NYSE:MRK) Shares Purchased by Intrinsic Value Partners LLCAugust 1 at 8:55 AM | marketbeat.comMGO One Seven LLC Sells 5,588 Shares of Merck & Co., Inc. (NYSE:MRK)August 1 at 8:55 AM | marketbeat.comCordatus Wealth Management LLC Boosts Holdings in Merck & Co., Inc. (NYSE:MRK)August 1 at 8:37 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Sold by Davis R M Inc.August 1 at 8:26 AM | marketbeat.comModera Wealth Management LLC Has $4.32 Million Position in Merck & Co., Inc. (NYSE:MRK)August 1 at 8:02 AM | marketbeat.comArkadios Wealth Advisors Acquires 8,909 Shares of Merck & Co., Inc. (NYSE:MRK)August 1 at 7:51 AM | marketbeat.comXTX Topco Ltd Buys 15,404 Shares of Merck & Co., Inc. (NYSE:MRK)August 1 at 7:46 AM | marketbeat.comGeneos Wealth Management Inc. Raises Stock Holdings in Merck & Co., Inc. (NYSE:MRK)August 1 at 7:23 AM | marketbeat.comLeerink Partnrs Has Negative Forecast for MRK Q3 EarningsAugust 1 at 5:41 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Price Target Lowered to $90.00 at Wells Fargo & CompanyJuly 31 at 10:41 AM | marketbeat.comNatixis Advisors LLC Sells 175,562 Shares of Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comLetko Brosseau & Associates Inc. Has $21.62 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comNorthRock Partners LLC Cuts Holdings in Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comSSA Swiss Advisors AG Takes Position in Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comTower Bridge Advisors Sells 4,200 Shares of Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comDearborn Partners LLC Sells 57,396 Shares of Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comFirst National Trust Co Trims Stock Holdings in Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comTredje AP fonden Has $82.83 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comEastern Bank Lowers Stock Position in Merck & Co., Inc. (NYSE:MRK)July 31 at 7:51 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?From Zero to Hero? Why GoPro's Rally Could Be More Than It SeemsBy Jeffrey Neal Johnson | July 24, 2025View From Zero to Hero? Why GoPro's Rally Could Be More Than It SeemsDon’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBy Chris Markoch | July 8, 2025View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonAnalysts Are Backing Qualcomm: Is a Breakout Coming?By Sam Quirke | July 22, 2025View Analysts Are Backing Qualcomm: Is a Breakout Coming?Golden Cross Alert: 3 Stocks With Serious Upside PotentialBy Chris Markoch | July 31, 2025View Golden Cross Alert: 3 Stocks With Serious Upside PotentialMRK, MOR, APM, and GNFT Company DescriptionsAptorum Group NASDAQ:APM$1.37 -0.18 (-11.61%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.38 +0.01 (+0.66%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.GENFIT NASDAQ:GNFT$3.82 -0.12 (-2.93%) As of 08/1/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/31/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Merck & Co., Inc. NYSE:MRK$79.27 +1.15 (+1.47%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$79.28 +0.02 (+0.02%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
